

## Beyond volatility targeting

### ■ Should the weight be $1/\sigma$ or $1/\sigma^2$ ?

In a past research note (*Understanding volatility targeting*, 4 October 2011) we have analysed the performance of simple asset allocation strategies that combine a passive index with cash. The weight on the index is inversely proportional to its volatility, in such a way that the volatility of the strategy itself is kept constant. In this document we study a more general set of strategies built so as to have a weight on the passive index equal to  $1/\sigma^\gamma$ . The goal of our analysis is to understand what determines the optimal choice of  $\gamma$  that maximises the Sharpe ratio in the long term. In particular, it would be interesting to establish under which conditions volatility targeting ( $\gamma=1$ ) is optimal in this sense.

### ■ The role of alpha, index volatility and kurtosis

A simple theoretical model which allows for time varying volatility provides some interesting insights. We find that the optimal choice depends on three parameters. The higher the expected return of the passive index, the lower the optimal exponent  $\gamma$ . The higher the average volatility of the index, the higher the optimal solution. Finally, the optimal  $\gamma$  is an increasing function of the volatility of volatility.

### ■ In practice the optimum is close to $1/\sigma^2$

When we plug realistic parameter values into our formula we invariably find that the highest Sharpe ratio is obtained by dividing by a factor that is close to the variance, not by the volatility.

18 June 2012

[www.ubs.com/investmentresearch](http://www.ubs.com/investmentresearch)**Giuliano De Rossi**Analyst  
[giuliano.de-rossi@ubs.com](mailto:giuliano.de-rossi@ubs.com)  
+44-20-7568 3072**James Sefton**Analyst  
[james.sefton@ubs.com](mailto:james.sefton@ubs.com)  
+44-20-7568 6078**David Jessop**Analyst  
[david.jessop@ubs.com](mailto:david.jessop@ubs.com)  
+44-20-7567 9882**Claire Jones**Associate Analyst  
[claire-c.jones@ubs.com](mailto:claire-c.jones@ubs.com)  
+44-20-7568 1873**Heran Zhang**Associate Analyst  
[heran.zhang@ubs.com](mailto:heran.zhang@ubs.com)  
+44 20756 83560

# Is volatility targeting optimal?

## Introduction

Volatility targeting strategies (VTSs) have recently received considerable attention, partly due to the encouraging performance of low volatility strategies. A VTS can be thought of as simple asset allocation strategy that combines a passive index with cash. The weight on the index is inversely proportional to its volatility, so that the volatility of the strategy itself is kept constant at its target level.

Volatility targeting is used to stabilise the volatility of a strategy...

We argued in a recent research note (*Understanding volatility targeting strategies*, 4 October 2011) that the Sharpe ratio of such a strategy should be higher than that of the passive index. A series of backtests, presented in the original note, suggest that this is indeed the case in the long term for all the stock market indices that we have considered.

...and tends to have positive impact on risk adjusted performance

Here we analyse a more general set of asset allocation strategies, in which the weight on the passive index can be proportional to any power of the index volatility, including the variance. Intuitively, choosing a weight that is proportional to a *high* power of  $\sigma$  would be effective in reducing volatility when the passive index is highly volatile. However, it would also result in highly leveraged positions when index volatility is particularly low.

Here we consider a generalisation of volatility targeting

The next sections formalise the intuition by deriving in a simple theoretical model the optimal balance between curbing volatility and stabilising weights.

## The model

Two assets are available, a passive index and cash. The latter earns a constant risk free return  $r$ . We consider a one factor stochastic volatility model of the returns to the index, which can be written as

Cash and a risky asset (index) are available

$$\begin{aligned} y_t &= \mu + \sigma_t \varepsilon_t \quad \text{where} \\ \sigma_t &\equiv \sigma_* e^{h_t/2}, \\ h_t &= \phi h_{t-1} + \eta_t \end{aligned} \tag{1}$$

Here  $y_t$  is the index return,  $\sigma_t$  is its volatility,<sup>1</sup>  $\varepsilon_t$  is a random variable (i.i.d. standard normal) which represents *transitory* shocks to volatility. The process  $h_t$  represents the fluctuations of the log variance  $\log \sigma_t^2$  around its long term mean  $\log \sigma_*^2$ . The innovation to  $h_t$ , which represents a *permanent* volatility shock, is i.i.d. and normally distributed:  $\eta_t \sim N(0, q)$ .  $\sigma_*^2$ ,  $\phi$  and  $q$  are constants. We assume  $0 < \phi < 1$  in order to impose stationarity.

We derive the results in a standard stochastic volatility model

The unconditional mean of  $h$  is zero, while its unconditional variance is given by

$$\sigma_h^2 \equiv \text{Var}(h_t) = \frac{q}{1 - \phi^2}.$$

<sup>1</sup> To be precise, conditional on  $\sigma_t$  the volatility of  $y_t$  is  $\sigma_t$ .

This model is the workhorse of the vast literature on stochastic volatility.

## Choosing the weights

Call  $w_t$  the weights on the index, so that the strategy returns are

$$w_t y_t + (1 - w_t) r.$$

We use weights that are inversely proportional to the volatility raised to the power of  $\gamma$ :

$$w_t \equiv \frac{\bar{\sigma}}{\sigma_t^\gamma} \quad (2)$$

where  $\bar{\sigma}$  is a constant target level.

It is important to bear in mind that we are implicitly assuming that volatility is known when the portfolio is rebalanced. We have shown in our original research note that, in practice, one can plug a volatility forecast from a simple model into (2) in order to keep volatility stable over time.

Different choices of  $\gamma$  result in different volatility driven strategies. Setting  $\gamma = 1$  corresponds to volatility targeting as defined in our original paper, i.e. it ensures that the conditional volatility of  $w_t y_t$  is constant over time. If  $\gamma = 0$  then the weight is constant, i.e. we hold the passive index and cash in fixed proportions. Finally, if  $\gamma$  is set equal to 2 then the weights are inversely proportional to the variance of the index.

The expectation of the excess return to the index is  $\mu - r \equiv \mu_*$ .

To compute the moments of the VTS we need to set a target volatility level in

(2),  $\bar{\sigma}$ . A natural choice is  $\bar{\sigma} = \sigma_*^\gamma \exp\left(-\frac{\sigma_h^2}{8} \gamma^2\right)$  which implies that the

expected weight on the index,  $E(w_t)$ , is equal to one for any value of  $\gamma$ . In other words, we are on average holding the index. The exponential in the formula can be thought of as a *convexity correction*, which is necessary because the model is nonlinear. In fact, Jensen's inequality implies that without the correction we would have

$$E(w_t) = E\left(\frac{\bar{\sigma}}{\sigma_t^\gamma}\right) = E\left(e^{-\gamma h_t / 2}\right) > e^{-\gamma E(h_t) / 2} = 1.$$

This is true regardless of the normality assumption, however the specific convexity correction used above depends on the assumption that  $h_t$  is Gaussian. In any case, the Sharpe ratio does not depend on the choice of  $\bar{\sigma}$  because (2) is linear in  $\bar{\sigma}$  and therefore the term disappears when we compute the ratio of mean to standard deviation.

The weight on the risky index is proportional to volatility raised to the power of  $\gamma$

$\gamma=0$  gives a passive strategy,  $\gamma=1$  is volatility targeting...

... and  $\gamma=2$  corresponds to *dividing by the variance*

Choosing the target volatility level

## The optimal strategy

The expected return of the strategy can be easily calculated:

Computing expected return...

$$E(w_t(y_t - r)) = \mu_*$$

It does not depend on  $\gamma$ , which means that all the strategies considered in the analysis have the same expected return, which is also the expected return of the passive index.

On noting that  $\varepsilon_t$  and  $h_s$  are independent for any  $s, t$  we can use the properties of the lognormal distribution to show that the variance of the returns to our strategy is given by<sup>2</sup>

...and variance

$$Var(w_t(y_t - r)) = \mu_*^2 \left[ \exp\left(\frac{\sigma_h^2}{4} \gamma^2\right) - 1 \right] + \sigma_*^2 \exp\left(\frac{\sigma_h^2}{4} (2(1 - \gamma)^2 - \gamma^2)\right). \quad (3)$$

Expression (3) is made up of two terms. The former accounts for the impact of the variability of weights on the variance of returns. As we argued in the introduction, the higher  $\gamma$  is, the more volatile the resulting weights. In practice, however, this term is negligible for realistic parameter values.

The variance accounts for the uncertainty on future weights

The latter term in (3) represents the contribution to the variance of the product  $w_t \sigma_t \varepsilon_t$ . It is worth noting that this term is minimised by choosing  $\gamma = 2$ .

It is easy to show that the expressions found in our original work are special cases of (3) with  $\gamma = 0$  (the passive index) and  $\gamma = 1$  (volatility targeting).

We are now in a position to compute the (squared) Sharpe ratio:

Computing the Sharpe ratio...

$$SR(\gamma)^2 = E(w_t(y_t - r))^2 / Var(w_t(y_t - r)).$$

Since the numerator is independent of  $\gamma$ , in order to maximise the Sharpe ratio we can look for the value of  $\gamma$  which minimises the denominator:

...and optimising

$$\min_{\gamma} Var(w_t(y_t - r)).$$

Note that the function is bounded from below (as it is nonnegative) and diverges as  $\gamma \rightarrow \infty$  or  $\gamma \rightarrow -\infty$ . We can set the first derivative to zero and analyse the solutions. This yields the equation


$$\frac{\gamma}{2 - \gamma} \frac{\mu_*^2}{\sigma_*^2} = \exp\left(\sigma_h^2 \left(\frac{1}{2} - \gamma\right)\right). \quad (4)$$

The value  $\gamma$  that solves (4) maximises the Sharpe ratio. It can be computed numerically given the parameter values. However, a graphical illustration can

<sup>2</sup> Details of the rather tedious algebra are available upon request.

help understanding how the expected return and volatility of the passive index (plus the volatility of its volatility) are related to the optimal strategy.

Figure 1: Solving for the optimal parameter gamma



Source: UBS quant.

The two sides of the equation are depicted in Figure 1. The optimal value of  $\gamma$ , found at the point where  $LHS=RHS$ , always lies between 0 (the passive strategy) and 2 (dividing by the variance). A simple comparative statics exercise shows that:

The factors that determine the optimal solution

1. The passive index is never optimal because the solution can never occur at  $\gamma = 0$
2. The steeper the trend  $\mu_*$ , the lower the optimal  $\gamma$  (increasing  $\mu_*$  moves the curve LHS upwards for  $\gamma > 0$ )
3. The higher the long term volatility  $\sigma_*$ , the higher the optimal  $\gamma$  (increasing  $\sigma_*$  moves the curve LHS downwards for  $\gamma > 0$ )
4. The more volatile volatility is (i.e. the higher  $\sigma_h^2$ ), the higher the optimal  $\gamma$  (increasing  $\sigma_h^2$  moves the curve RHS upwards).

## Weights close to $1/\sigma^2$ are optimal in most cases

Alternatively, the same result can be expressed (after dividing by  $\exp(\sigma_h^2/2)$  and rearranging) as

We plug realistic parameter values into the formula


$$SR^{*2} = n \frac{e^{-\sigma_h^2 \gamma}}{2 - \gamma}$$

where  $SR^*$  is the annualised Sharpe ratio of the passive index and  $n$  the number of subperiods in a year (e.g.  $n=52$  for a weekly model).

Because the expression depends only the passive Sharpe ratio and the volatility of volatility parameter  $\sigma_h$ , it is possible to illustrate the optimal choice of  $\gamma$  in a two-dimensional plot (Figure 2 for daily data, Figure 3 for weekly).

The parameter  $\sigma_h^2$  is typically estimated to be between 0.5 and one for equity indices. If, for example, it were equal to 0.6 then assuming a median volatility of 20% would imply that the first and third quartiles of the stationary distribution of volatility are 15.4% and 26%.

Figure 2: Optimal choice of  $\gamma$ , daily data



Source: UBS quant. Sharpe ratios are annualised. The long term estimates for S&P 500, used in our original note *Understanding volatility targeting*, are 0.43 for the Sharpe ratio and 0.576 for the stationary variance of  $h$  (the point shown in the figure). The corresponding optimal choice of  $\gamma$  from solving (4) is 1.99.

The optimal solution seems to be affected more by the Sharpe ratio than by the fourth moment of the distribution. What is striking is that, for any realistic value of the parameters,  $\gamma$  is not far from 2. This can be explained by the fact that the first term in (3) is typically negligible while the second term,


The optimal  $\gamma$  is typically close to 2

$$\sigma_*^2 \exp\left(\frac{\sigma_h^2}{4} (2(1-\gamma)^2 - \gamma^2)\right), \quad (5)$$

is minimised at  $\gamma = 2$ . The two terms involving  $\gamma$  in (5) have a straightforward interpretation: The former is related to the variance of the term  $\sigma_t^{1-\gamma} \varepsilon_t$  (i.e. the unpredictable component of return  $\sigma_t \varepsilon_t$  divided by  $\sigma_t^\gamma$ ) while the latter stems from the convexity correction. Setting  $\gamma = 1$  (i.e. volatility targeting) minimises the first term as the volatility is kept constant at the target, but it also results in a larger value of the second term compared to the case where  $\gamma = 2$ . Dividing by the variance increases convexity and this has a positive effect on the Sharpe ratio.

Assuming weekly data (Figure 3) does not change the result significantly.

Figure 3: Optimal choice of  $\gamma$ , weekly data



Source: UBS quant. Sharpe ratios are annualised.

Expression (5) can be used to gauge the improvement in Sharpe ratio that is obtained by selecting the optimal  $\gamma$ . The variance is approximately equal to

$\sigma_*^2 \exp\left(\frac{\sigma_h^2}{2}\right)$  for the passive index,  $\sigma_*^2 \exp\left(-\frac{\sigma_h^2}{4}\right)$  for volatility targeting

and  $\sigma_*^2 \exp\left(-\frac{\sigma_h^2}{2}\right)$  for  $\gamma = 2$ . Hence, assuming that  $\sigma_h^2$  is between 0.5 and

one we conclude that volatility targeting improves the Sharpe ratio compared to the passive index by a factor of 13 to 28%, while dividing by the variance results in an improvement between 20 and 45%.

## Conclusion

We considered a set of simple asset allocation rules that can be viewed as a generalisation of VTSs. In particular, we allow the weight on the passive index to be inversely proportional to volatility raised to the power of  $\gamma$ , a free parameter. We then asked what is the optimal choice of  $\gamma$ , i.e. the one which results in the maximum Sharpe ratio. The answer is that, for realistic parameter values, the exponent should always be slightly below 2. In other words, weights that are roughly proportional to the variance (not to the standard deviation, i.e. the volatility) of the index seem to be optimal.

The improvement in Sharpe ratio compared to the passive strategy

The strategy that maximises risk adjusted performance is typically obtained for  $\gamma=2$

The analysis also gives some guidance as to which factors determine the optimal weighting scheme. We find that the solution always lies between zero (holding the passive index) and 2 (dividing by the variance). It will be closer to 2 when the expected return to the passive index is low, when the average volatility of the index is high or when the uncertainty surrounding future volatility is high.

The factors that determine the optimal solution



---

### ■ Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

## Required Disclosures

This report has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. This report has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit [www.ubs.com/disclosures](http://www.ubs.com/disclosures). The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

### UBS Investment Research: Global Equity Rating Allocations

UBS 12-Month Rating	Rating Category	Coverage <sup>1</sup>	IB Services <sup>2</sup>
Buy	Buy	51%	34%
Neutral	Hold/Neutral	40%	35%
Sell	Sell	9%	15%
UBS Short-Term Rating	Rating Category	Coverage <sup>3</sup>	IB Services <sup>4</sup>
Buy	Buy	less than 1%	25%
Sell	Sell	less than 1%	17%

1:Percentage of companies under coverage globally within the 12-month rating category.

2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category.

4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

Source: UBS. Rating allocations are as of 31 March 2012.

### UBS Investment Research: Global Equity Rating Definitions

UBS 12-Month Rating	Definition
Buy	FSR is > 6% above the MRA.
Neutral	FSR is between -6% and 6% of the MRA.
Sell	FSR is > 6% below the MRA.
UBS Short-Term Rating	Definition
Buy	Buy: Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.
Sell	Sell: Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.

## KEY DEFINITIONS

**Forecast Stock Return (FSR)** is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months.

**Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium).

**Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation.

**Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case.

**Equity Price Targets** have an investment horizon of 12 months.

## EXCEPTIONS AND SPECIAL CASES

**UK and European Investment Fund ratings and definitions are:** Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Sell: Negative on factors such as structure, management, performance record, discount.

**Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

**UBS Limited:** Giuliano De Rossi; James Sefton; David Jessop; Claire Jones; Heran Zhang.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

## Global Disclaimer

This document has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. This document has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ('the Information'), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

**United Kingdom and the rest of Europe:** Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised and regulated by the Financial Services Authority (FSA). **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:** Prepared by UBS Menkul Değerler AS on behalf of and distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 2499). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Securities CJSC. **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. **Italy:** Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this document, the document is also deemed to have been prepared by UBS Italia Sim S.p.A. **South Africa:** Distributed by UBS South Africa (Pty) Limited, an authorised user of the JSE and an authorised Financial Services Provider. **Israel:** UBS Limited and its affiliates incorporated outside Israel are not licensed under the Investment Advice Law. This material is being issued only to and/or is directed only at persons who are Sophisticated Investors within the meaning of the Israeli Securities Law, and this material must not be relied on or acted upon by any other persons. Whilst UBS Limited holds insurance for its activities, it does not hold the same insurance that would be required for an investment advisor or investment marketer under the relevant Investment Advice Law Regulations. **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a foreign closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Hong Kong:** Distributed by UBS Securities Asia Limited. **Singapore:** Distributed by UBS Securities Pte. Ltd. [Mica (p) 016/11/2011 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to institutional investors only. Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. **Australia:** Distributed by UBS AG (Holder of Australian Financial Services License No. 231087) and/or UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098). The Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. **New Zealand:** Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor. **Dubai:** The research prepared and distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (253825-x). **India:** Prepared by UBS Securities India Private Ltd. 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000 SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment) INB010951437.

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2012. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

